Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real-Life Experience in the Lazio Region

March 2025 in “ International Journal of Dermatology ”

Giacomo Caldarola, Lorenzo Maria Pinto, Maria Cristina Acri, Lorenzo Ala, Nicoletta Bernardini, Laura Colonna, Laura Diluvio, Domenico Giordano, Enrico Matteini, Francesco Moro, Maria Beatrice Pupa, Luca Bianchi, Ketty Peris, Alfredo Rossi

Baricitinib alopecia areata

From the encyclopedia

Baricitinib →

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary This source does not report any results or findings, as no abstract is provided.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The document discusses the effectiveness of Baricitinib in treating patients with alopecia areata who have experienced a current episode lasting longer than 8 years. This Italian multicenter real-life study conducted in the Lazio region highlights the potential benefits of Baricitinib for long-term alopecia areata sufferers. However, specific details about the study's methodology, sample size, and results are not provided in the text. The authors did not receive specific funding for this work, and the document does not include an abstract.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study

September 2024 in “Journal of the European Academy of Dermatology and Venereology”

This study found that baricitinib significantly reduced hair loss in patients with severe alopecia areata, decreasing the mean SALT score from 96.6 to 48 over 24 weeks, with no patients dropping out and only mild adverse events in 12.7% of participants.

research Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients

January 2024 in “Acta dermato-venereologica”

Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

research Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

3 citations , June 2023 in “Journal of dermatological treatment”

This study found that patients with severe alopecia areata who experienced meaningful scalp hair regrowth showed greater improvements in health-related quality of life and reduced anxiety and depression compared to those with no or minimal regrowth.